Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03202186
Other study ID # BHR-401-301
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date August 1, 2017
Est. completion date December 6, 2018

Study information

Verified date March 2019
Source BHR Pharma, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the clinical trial is to demonstrate superiority of BHR401 (oral micronized progesterone) versus placebo as a monotherapy for moderate to severe VMS in postmenopausal women. Three different doses of BHR-401 (200 mg, 300 mg or 400 mg) will be tested against placebo in hierarchical order, starting with the highest dose. Superiority will be defined as a significant (significance level α = 0.05) reduction of moderate to severe VMS frequency compared to placebo at treatment week 12 (the primary efficacy endpoint of the study).


Recruitment information / eligibility

Status Terminated
Enrollment 55
Est. completion date December 6, 2018
Est. primary completion date December 6, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Willing and able to provide written informed consent

- Adult (= 18 years), postmenopausal women, where postmenopause is defined as

- at least 12 months of spontaneous amenorrhea, or

- 6 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) levels > 40 mIU/ml, or

- status at least 6 weeks after bilateral oophorectomy with or without hysterectomy

- Non-smoker

- Mammography without pathological findings obtained within routine medical care no longer than 12 months prior to screening visit

- Cervical smear (Papanicolaou test) without pathological findings (i.e. < III) obtained no longer than 12 months prior to screening visit

- In addition subjects need to fulfil the following criterion in order to be randomized (i.e. to enter the treatment period):

- A minimum of 50 moderate to severe VMS episodes over the last 7 consecutive days prior to the baseline visit, as documented in the patient diary.

Exclusion Criteria:

- Use of any hormone replacement therapy (including phytoestrogens and other plant-derived sex hormones) during the previous 12 weeks prior to screening

- Ongoing or suspicion of any estrogen-dependent malignancy.

- Endometrial thickness = 5 mm at screening visit

- Any history or current presence or suspicion of breast cancer, including carcinoma in situ and other pre-cancerous conditions

- Active malignant disease of any organ system (except for basal localized basal cell carcinoma of the skin) or history thereof in the last 5 years prior to screening visit

- Vaginal bleeding due to unidentified reason within 6 weeks prior to screening

- Ongoing venous thromboembolic event or history thereof within 12 months prior to screening visit

- Known severe renal insufficiency (defined as glomerular filtration rate, GFR < 30 mg/min/1.73 m²) at screening visit

- Known lipid metabolism disturbances of genetic origin (e.g. familial hypercholesterolemia, familial hypertriglyceridemia)

- Acute or chronic liver diseases or a history of liver disease with liver enzymes having not normalized since then

- Severe disturbances of hepatic function (including porphyria), hepatic tumors, also in medical history

- Rotor syndrome or Dubin-Johnson syndrome

- History of icterus or generalized pruritus during a previous pregnancy

- History of myocardial infarction, stroke or transient ischemic attack or severe cardiac disease, including symptomatic chronic heart failure

- Ongoing major depression

- Subjects who currently take or are planned to commence treatment with SSRI, SNRI for any reason during the course of the study

- Diabetes mellitus

- Hypersensitivity to progesterone or excipients (e.g. soy) of the study medication

- Medical history of HIV infection

- Concomitant diseases or therapies that may cause VMS or affect VMS frequency or severity, e.g. but not limited to poorly controlled thyroid dysfunction (thyroid medication should be stable for at least 12 weeks prior to screening and TSH levels should be within range), fear disorders (e.g. panic disorders)

- Participation in a clinical trial or intake of any investigational medicinal product within three months prior to screening visit

- Previous participation in this clinical trial

- Known or suspected drug or alcohol abuse

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Progesterone oral capsule
Oral capsule treatment
Placebo oral capsule
Oral capsule treatment

Locations

Country Name City State
Germany Fachärztin für Gynäkologie und Geburtshilfe Bernburg

Sponsors (1)

Lead Sponsor Collaborator
BHR Pharma, LLC

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of adverse events (AEs) and serious adverse events (SAEs) 12 weeks
Other Kupperman Index Change vs. baseline of postmenopausal symptoms as assessed by the physician by means of the Kupperman Index inventory after 4 weeks and 12 weeks of treatment 4 and 12 weeks
Other Sleep quality assessed by means of the Pittsburgh Sleep Quality Index (PSQI) Change in subjective sleep quality vs. baseline as assessed by means of the Pittsburgh Sleep Quality Index (PSQI) after 4 weeks and 12 weeks of treatment 4 and 12 weeks
Primary Frequency of moderate to severe vasomotor symptoms at 12 weeks the change vs. baseline of the frequency of moderate or severe VMS episodes (per day) after 12 weeks of treatment with BHR-401or placebo 12 weeks
Secondary Frequency of moderate to severe vasomotor symptoms at 4 weeks the change vs. baseline of the frequency of moderate or severe VMS episodes (per day) 4 weeks
Secondary Severity of vasomotor symptoms at 12 weeks the change vs. baseline of the secerity of moderate or severe VMS episodes (per day) 12 weeks
Secondary Severity of vasomotor symptoms at 4 weeks the change vs. baseline of the severity of moderate or severe VMS episodes (per day) 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT05617287 - An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Perimenopause and Menopause N/A
Withdrawn NCT04258410 - Quercetin for Cardio-Skeletal Muscle Health and Estrogen Deficiency Phase 4
Recruiting NCT05912309 - Effects of Time-restricted Eating and Exercise Training on Skeletal Muscle Mass Quantity, Quality and Function in Postmenopausal Women With Overweight and Obesity N/A
Completed NCT04079218 - Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial Phase 4
Active, not recruiting NCT03681678 - Laser Therapy for Treatment of Urogenital Symptoms in Women
Completed NCT03082040 - A Home-based Breathing Training on Menopausal Symptoms N/A
Recruiting NCT06048965 - Asia Pacific Menopause Federation Menopause Consensus
Terminated NCT03037554 - The Effects of Lateralized Thermal Sleepwear on Sleep, Skin Temperature and Skin Moisture in Menopausal Women N/A
Completed NCT03150407 - Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness N/A
Completed NCT04336891 - Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.
Not yet recruiting NCT04190927 - A New Hormone Replacement Paradigm: Physiologic Restoration Study Phase 4
Completed NCT03178695 - Inovium Ovarian Rejuvenation Trials Phase 1
Completed NCT05408273 - Vitamin D and Microvascular Function in Postmenopausal Women
Recruiting NCT04031456 - Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients Phase 2/Phase 3
Completed NCT05062057 - Menopause Racing Heart Study
Completed NCT05396261 - a Flexible Wound Dressing for the Management of Genital Skin Conditions N/A
Completed NCT06154798 - World Digital Detox Program for Enhancing Women's Health & Well-being N/A
Completed NCT03752060 - The Clinical Utility of Resistance Training for Improving Cardiovascular Disease Risk in Post-Menopausal Women N/A
Recruiting NCT06074120 - Low-level Laser Therapy in Genitourinary Symptoms of Menopause N/A
Recruiting NCT06192329 - Hot Water Therapy for the Treatment of Menopause-related Hot Flashes N/A